Fujifilm Holdings (FUJIFILM Holdings): BofA Upgrades Fujifilm Holdings to Buy: Bio CDMO Negatives Largely Priced In and BI Cost Reductions Form the Core Re-rating Thesis

Overview

The report upgrades Fujifilm Holdings from Neutral to Buy, primarily because its valuation may have bottomed, near-term earnings risks in Bio CDMO are largely priced in, and the Business Innovation spin-off could accelerate cost reductions. BofA lowers its earnings expectations for Healthcare, particularly Bio CDMO, but raises its BI and Electronics forecasts, resulting in increases of up to 2% in group operating profit forecasts through FY3/31, while maintaining the ¥4,000 target price.

Core views

Regarding the rating and group earnings, the report upgrades Fujifilm Holdings from Neutral to Buy and maintains its ¥4,000 target price. Although the Bio CDMO forecast was lowered, BofA raised its Business Innovation and Electronics forecasts, increasing operating profit estimates through FY3/31 by up to 2%. Revenue forecasts were raised from the previous FY3/27 ¥3,497,490mn, FY3/28 ¥3,648,990mn, and FY3/29 ¥3,844,410mn to ¥3,568,080mn, ¥3,732,150mn, and ¥3,963,690mn, respectively. However, EPS forecasts were lowered from ¥244.79, ¥285.88, and ¥324.98 to ¥235.99, ¥274.09, and ¥316.43, respectively, indicating that the revenue upgrades following changes in the business mix did not fully translate into higher per-share earnings estimates. FY3/27 operating profit is forecast at ¥372.8bn, up 6.5% YoY, broadly in line with consensus and above company guidance of ¥365.0bn, with disposals of idle assets providing partial support. FY3/28 operating profit is forecast at ¥434.3bn, up approximately 17% YoY and 4% above consensus, with BI providing the main incremental contribution. FY3/29 operating profit is forecast at ¥502.6bn, up 15.7% YoY and also 4% above consensus. Free cash flow is expected to turn from negative ¥48.074bn in FY3/27 to positive ¥123.726bn in FY3/28, rising further to ¥189.626bn in FY3/29. Valuation is the first pillar of the rating upgrade. The current share price implies 7.5x FY3/28 EV/EBITDA and 0.92x PBR, while BofA forecasts a 12% operating profit CAGR over the next five years. On a two-year forward basis, 7.5x EV/EBITDA corresponds to an 11% EBITDA CAGR over the next three years. Within its medical technology coverage, Fujifilm's valuation is higher only than Menicon's and is the lowest among large-cap companies. The report also notes that although the stock traded below 1x PBR for nearly two years during 2016–2018, since 2020, 1x PBR has become a psychological support level due to the Fuji Xerox restructuring and improved profitability in the Imaging business, driven by Instax volume growth and the premiumization of digital cameras. The current trailing twelve-month PBR is 0.98x, while the forecast FY3/28 PBR is 0.92x. A 1x FY3/28 PBR implies a share price of approximately ¥3,550, while the ¥4,000 target price corresponds to 1.12x PBR and 8.7x FY3/28 EV/EBITDA. BofA uses an SOTP valuation and, due to uncertainty caused by the outlook downgrade after 1Q, lowers the valuation discount factor for Bio CDMO from 85% to 80%, while cross-checking the target price using DCF and EV/EBITDA. For Bio CDMO, after 1Q the company widened its FY3/27 operating loss guidance from ¥40.0bn to ¥70.0bn. The reasons included delays in establishing the production system and low utilization at large-scale U.S. tank capacity, with an impact of approximately ¥12.0–13.0bn; weak orders at small- and mid-scale facilities, with an impact of approximately ¥10.0bn; and an unexpected shutdown of small- and mid-scale U.S. tanks following an unannounced FDA inspection, with an impact of approximately ¥7.0–8.0bn. The final classification following Form 483 appears to be VAI, meaning voluntary corrective action is required. The report notes that Form 483 is not uncommon and therefore assumes no further earnings impact, consistent with the company's 1Q assumptions, and expects operations to resume in September. However, execution issues at large-scale tanks and weak orders at small- and mid-scale facilities reflect shortcomings in commercial and operational execution, and BofA remains cautious on the business's medium- to long-term fundamentals. At its February briefing, the company set FY3/31 targets of ¥700.0bn in revenue and an EBITDA margin of approximately 35%, while BofA forecasts only ¥656.7bn and 19%, implying a substantial shortfall against the targets. Despite its cautious medium- to long-term assessment, the report believes Bio CDMO's near-term risks are largely priced in. BofA forecasts an FY3/27 operating loss of ¥68.4bn for the business, broadly consistent with company guidance, and expects the loss to narrow to ¥26.7bn in FY3/28, within the market's expected loss range of approximately ¥20.0–30.0bn. It does not expect the business to turn profitable at the operating level until FY3/30. The company is expected to provide an FY3/28 outlook when it reports 2Q results in November. If that outlook is broadly consistent with BofA's forecast, it would not constitute a new negative surprise and could instead remove residual uncertainty weighing on the share price by improving visibility. The company had previously committed to achieving operating break-even in Bio CDMO in FY3/28, but the report believes this has become difficult to achieve through organic recovery alone. Selling some loss-making small- and mid-scale facilities or businesses could allow resources to be concentrated on larger-scale operations with stronger strategic fit and profitability, creating additional upside potential. However, because the timing and terms are uncertain, BofA has not incorporated this into its forecasts. The report also conducts scenario analysis on impairment risk. BofA estimates that Bio CDMO will have approximately ¥1.4tn in depreciable fixed assets at the end of FY3/27. Assuming a 20%–30% impairment and applying a 1x FY3/28 PBR results in a share price of approximately ¥3,200–3,400, leading it to conclude that downside risk to the share price would remain relatively limited even if an impairment occurred. The company uses U.S. GAAP, under which the carrying value of tangible fixed assets must first be compared with undiscounted future cash flows before an impairment is recognized, resulting in a higher recognition threshold than under IFRS. On this basis, the report considers near-term impairment risk limited and states that the company expressed a similar view in discussions. Business Innovation is the second major source of re-rating potential. BI primarily comprises office multifunction devices, printers, and related solutions and maintenance services. It is a mature cash-generating business, but the market continues to contract as paper-based workflows migrate to digital formats. BofA forecasts a -1% revenue CAGR for BI over the next five years, below consensus of 1%. Earnings improvement is not expected to come from revenue growth, but from restructuring, procurement synergies, and industry consolidation. The company plans to consider a partial spin-off and listing of BI, with Fujifilm Holdings expected to retain a stake of slightly less than 20% and the remaining shares distributed to existing shareholders as an in-kind dividend before the listing. The transaction is expected to take place within two to three years. The report believes the spin-off will enhance BI's decision-making independence, facilitate integration across development, production, sales, logistics, and back-office functions, and allow the parent company to concentrate resources on growth areas such as Healthcare and Electronics. BI's cost improvements could exceed current consensus expectations. BofA incorporates ¥19.5bn of restructuring expenses in FY3/27, comprising ¥11.5bn for Graphic Communication and ¥8.0bn for Office Solutions. The company expects approximately ¥10.0bn in cost-reduction benefits in FY3/28, while BofA conservatively incorporates only ¥5.0bn. Meanwhile, the absence of ¥31.0bn in gains from idle asset disposals recognized in FY3/27 will weigh on profit, but ¥5.0bn in cost reductions and a ¥10.0–15.0bn decline in restructuring expenses could provide support. BofA forecasts BI FY3/28 operating profit of ¥67.9bn, 17% above consensus, and a five-year operating profit CAGR of 3%, above consensus of 1%. Its forecasts do not yet directly incorporate the spin-off transaction itself and reflect only progress in cost reductions. Potential subsequent measures include improving procurement terms through the joint procurement company established with Konica Minolta, consolidating procurement categories and suppliers, jointly developing and producing toner, and, over the medium term, integrating development and production sites, streamlining model lineups, and consolidating logistics networks and repair-parts inventories. Electronics provides a third source of earnings support. Recent growth has been driven by structural demand for semiconductor materials and data tape within Advanced Functional Materials. BofA expects demand for liquid semiconductor materials to grow by approximately 6%–7% annually, driven by increased production of advanced semiconductors related to generative AI, process miniaturization, more complex interconnect structures, and broader adoption of advanced packaging. Fujifilm is gaining share due to its product positioning and stable supply capabilities, and its growth could exceed that of the market. Data tape accounts for 20%–30% of the AF Materials business, and 1Q revenue appears to have nearly doubled YoY. Because it can physically isolate cold data from networks, adoption for cybersecurity applications is increasing. With only Fujifilm and Sony now remaining as industry suppliers, rising market concentration also benefits the company. BofA raised its forecasts following the strong 1Q performance, but it still expects FY3/31 semiconductor materials revenue of ¥473.5bn, below the company's ¥500.0bn target. Electronics is forecast to deliver a 13% operating profit CAGR over the next five years, in line with consensus, so no significant additional upside is currently incorporated. However, forecasts could be raised further if the strength continues. Overall, the report's re-rating thesis is not that Bio CDMO's medium- to long-term fundamentals have already strengthened, but that its near-term losses and impairment concerns are largely reflected in the valuation. If the November 2Q update improves visibility, these overhangs could ease. At the same time, the BI spin-off and industry consolidation enhance the credibility of cost reductions, while Electronics continues to provide structural growth. Together, these factors support a recovery in Healthcare and BI valuations over the next twelve months and underpin the maintained ¥4,000 target price and upgrade to Buy.

Analysis framework

The report first reassesses earnings for each business segment, combining the downgrade to Bio CDMO with upgrades to BI and Electronics in its group forecasts and comparing them with company guidance and Visible Alpha consensus. It then conducts an SOTP valuation based on FY3/28 segment EBITDA and cross-checks the result against DCF, EV/EBITDA, and historical PBR ranges. For Bio CDMO, the report breaks down the three sources of the deterioration in 1Q loss guidance and separately evaluates the near-term recovery, long-term operating targets, and fixed-asset impairment scenarios. For BI and Electronics, it assesses changes in earnings based on industry demand, organizational adjustments, cost synergies, the competitive landscape, and five-year growth forecasts.

Methodology notes

• Valuation MethodSOTP Segment Valuation

  SOTP Segment Valuation

  Because Fujifilm operates Healthcare, Electronics, Business Innovation, and Imaging businesses with different growth cycles and risk profiles, the report applies comparable multiples separately to each business's FY3/28 EBITDA and then deducts items such as net debt to calculate the group's theoretical value. The valuation discount factor for Bio CDMO was lowered from 85% to 80%.

• Valuation MethodDCF Discounted Cash Flow

  DCF Cross-check

  The report uses the discounted value of future cash flows to cross-check the ¥4,000 target price derived from SOTP rather than using DCF as the sole valuation basis.

• Valuation MethodEV/EBITDA valuation

  EV/EBITDA Multiple and Growth Alignment

  The report compares the current 7.5x FY3/28 EV/EBITDA with an 11% EBITDA CAGR over the next three years and the valuations of medical technology peers, and notes that the target price corresponds to 8.7x FY3/28 EV/EBITDA.

• Valuation MethodPB valuation

  Historical PBR Floor and Impairment Scenario

  The report views approximately 1x PBR as a psychological support level since 2020 and uses 1x FY3/28 PBR to derive a share price of ¥3,550, while also testing a scenario of approximately ¥3,200–3,400 following a 20%–30% impairment of Bio CDMO fixed assets.

• (Out-of-vocabulary Method)

  Segment Earnings Forecasts and Market Consensus Comparison

  The report forecasts revenue, profit, and cost changes for Bio CDMO, BI, and Electronics individually, then compares them with company targets and market consensus to identify risks already priced in and potential earnings upside not yet reflected.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Fujifilm Holdings (4901.T; ADR FUJIY)

  The report believes the company will benefit from BI cost reductions, structural growth in Electronics, and the easing of near-term uncertainty in Bio CDMO, creating opportunities for earnings and valuation recovery.

  Strengths

  A diversified business portfolio stabilizes near-term earnings; BI has cash-generating characteristics and cost-reduction potential; semiconductor materials benefit from strong product positioning and stable supply capabilities; data tape is supported by cybersecurity demand and increasing industry concentration.

  Weaknesses

  Bio CDMO faces issues in commercial execution, capacity utilization, and orders at small- and mid-scale facilities; the office printing market in which BI operates is contracting over the long term; some group earnings remain affected by one-time asset disposal gains and restructuring expenses.

  Comparison

  The current two-year forward EV/EBITDA is 7.5x, compared with a three-year EBITDA CAGR of 11%. Within BofA's medical technology coverage, the valuation is the second lowest and the lowest among large-cap companies.

  Risks

  Unexpected declines in Bio CDMO capacity utilization, weakening semiconductor markets, poor overseas Healthcare promotion performance, and Bio CDMO cash generation occurring later than expected.

Key data

• Rating ChangeUpgraded from Neutral to BuyTarget price maintained
• Target Price¥4,000; ADR US$12.90The report states that this represents 22% upside from the current share price
• Current Price¥3,319; ADR US$10.29Price reference on the report's cover page
• Current Valuation7.5x FY3/28 EV/EBITDA; 0.92x FY3/28 PBRCorresponding to the report's forecast 12% operating profit CAGR over the next five years
• FY3/27 Group Operating Profit¥372.8bnUp 6.5% YoY, broadly in line with consensus and above company guidance of ¥365.0bn
• FY3/28 Group Operating Profit¥434.3bnUp approximately 17% YoY and 4% above consensus
• FY3/29 Group Operating Profit¥502.6bnUp 15.7% YoY and 4% above consensus
• FY3/28 Free Cash Flow¥123.726bnTurning positive from negative ¥48.074bn in FY3/27
• Bio CDMO FY3/27 Loss GuidanceWidened from ¥40.0bn to ¥70.0bnThe company lowered its outlook with its 1Q results
• Bio CDMO Operating Profit ForecastFY3/27 -¥68.4bn; FY3/28 -¥26.7bnThe FY3/28 forecast is within the market's expected loss range of ¥20.0–30.0bn
• Bio CDMO FY3/31 Target ComparisonCompany targets revenue of ¥700.0bn and an EBITDA margin of approximately 35%; BofA forecasts ¥656.7bn and 19%The report expects the company to miss its medium- to long-term targets
• Bio CDMO Depreciable Fixed AssetsApproximately ¥1.4tnForecast at the end of FY3/27; a 20%–30% impairment and 1x PBR imply a share price of approximately ¥3,200–3,400
• BI FY3/28 Operating Profit¥67.9bn17% above market consensus
• BI Restructuring and Cost ReductionFY3/27 restructuring expenses of ¥19.5bn; FY3/28 cost reductions of ¥5.0bn incorporatedThe company expects approximately ¥10.0bn in cost reductions, while BofA uses a more conservative assumption
• BI Five-year Growth ForecastRevenue CAGR -1%; operating profit CAGR 3%Compared with consensus of 1% and 1%, respectively
• Liquid Semiconductor Materials Demand GrowthApproximately 6%–7% annuallyDriven by advanced semiconductors, generative AI, process miniaturization, and advanced packaging
• Data Tape PerformanceAccounts for 20%–30% of AF Materials, with 1Q revenue nearly doubling YoYGrowth driven by cybersecurity demand and supplier concentration
• Electronics Five-year Operating Profit CAGR13%In line with market consensus

Impact & implications

The report believes that downward revisions to Bio CDMO's medium- to long-term targets do not preclude a re-rating of the stock over the next twelve months because the FY3/28 loss is already close to market expectations and the November update could reduce near-term uncertainty. The BI spin-off and industry consolidation increase the likelihood of sustained cost reductions, which could support profit despite structural revenue declines, while Electronics provides growth through semiconductor materials and data tape. If these pathways materialize, group earnings growth, a return to positive cash flow, and a valuation recovery from below 1x PBR would jointly support the target price. However, the report does not assume that a sale of Bio CDMO facilities or the BI spin-off itself will directly contribute to forecast profit.

Risks

• If establishment of the production system, capacity utilization, and orders at small- and mid-scale facilities for Bio CDMO's large-scale tanks continue to deteriorate, losses could exceed current forecasts.
• The report remains cautious on Bio CDMO's medium- to long-term fundamentals and expects FY3/31 revenue and EBITDA margin to be significantly below company targets.
• If the semiconductor market enters a downturn, it could weaken demand, earnings, and valuation support for Electronics.
• If promotional and marketing effectiveness in the overseas Healthcare business remains weak, it would create downside risk to the target price.
• If Bio CDMO takes longer than expected to generate cash flow, it would create downside risk to the target price.

What to watch

• Monitor the 2Q update expected in November and the company's first FY3/28 Bio CDMO outlook to see whether it is close to the market's expected loss range of ¥20.0–30.0bn.
• Monitor whether the small- and mid-scale U.S. tanks resume operations in September as expected and whether remediation related to Form 483 has any additional earnings impact.
• Monitor whether the company disposes of some loss-making small- and mid-scale Bio CDMO facilities or businesses; BofA has not incorporated this possibility into its forecasts.
• Monitor the timing, ownership structure, and implementation terms of the partial BI spin-off and listing plan, with the transaction currently expected to take place within two to three years.
• Monitor announcements regarding BI cost reductions, including improved procurement terms, supplier consolidation, joint toner development and production, and the integration of sites, logistics, and parts inventories.
• Monitor whether strong growth in semiconductor materials and data tape continues and whether Electronics forecasts are raised further.
• Monitor whether Imaging growth reaccelerates, which the report identifies as a potential upside factor for group earnings forecasts.